Respiratory Medicine
Volume 103, Issue 7 , Pages 963-974 , July 2009

Smoking cessation in chronic obstructive pulmonary disease

  • Donald P. Tashkin

      Affiliations

    • Department of Medicine, David Geffen School of Medicine at UCLA, 37-131 Center for Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095-1690, USA
    • Corresponding Author InformationCorresponding author. Tel.: +310 825 3163; fax: +310 206 5088.
    • ,
  • Robert P. Murray

      Affiliations

    • Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, MS7, 820 Sherbrook Street, Winnipeg, MB R3A 1R9, Canada

Received 24 September 2008 ,Accepted 19 February 2009.

References 

  1. Centers for Disease Control and Prevention. National Center for Health Statistics, Health United States, 2003, With Chartbook on Trends in the Health of Americans. Accessed Dec 5 2006; http://cdc.gov/nchs/data/hus/tables/2003/03hus031.pdf.
  2. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs − United States, 1995−1999. MMWR Morb Mortal Wkly Rep. 2002;51:300–303
  3. U.S. Department of Health and Human Services. The health consequences of smoking: a report of the surgeon general. Office Smoking Health. 2004;
  4. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American heart Association. American Heart Association Task Force on Risk Reduction. Circulation. 1997;96:3243–3247
  5. U.S. Department of Health and Human Services. Tobacco use among U.S. racial/ethnic minority groups − African Americans, American Indians and Alaska natives, Asian Americans and Pacific Islanders, and Hispanics: a report of the surgeon general. Atlanta, GA: USKHHS, CDC, 1998. Accessed Dec 5 2005; http://www.cdc.gov/tobacco/data_statistics/sgr_1998/index.htm.
  6. Global Initiative for chronic obstructive lung disease (GOLD). Guidelines: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated December 2007. Accessed Sept 2008; http://www.goldcopd.org.
  7. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance − United States, 1971−2000. MMWR Surveill Summ. 2002;51:1–16
  8. Petty TL. Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention. Chest. 2000;117:326S–331S
  9. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD international survey. Eur Respir J. 2002;20:799–805
  10. National Heart Blood and Lung Institute. Morbidity & Mortality. 2007 Chartbook on Cardiovascular, Lung, and Blood Diseases. Accessed Mar 17 2008; http://www.nhlbi.nih.gov/resources/docs/07a-chtbk.pdf.
  11. Arias E, Smith BL. Deaths: preliminary data for 2001. Natl Vital Stat Rep. 2003;51:1–44
  12. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121:121S–126S
  13. Mayer AS, Newman LS. Genetic and environmental modulation of chronic obstructive pulmonary disease. Respir Physiol. 2001;128:3–11
  14. Shaheen SO, Barker DJ, Holgate ST. Do lower respiratory tract infections in early childhood cause chronic obstructive pulmonary disease?. Am J Respir Crit Care Med. 1995;151:1649–1651(discussion 1651–2)
  15. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res. 2001;2:20–26
  16. Sparrow D, O'Connor G, Weiss ST. The relation of airways responsiveness and atopy to the development of chronic obstructive lung disease. Epidemiol Rev. 1988;10:29–47
  17. Chen JC, Mannino DM. Worldwide epidemiology of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 1999;5:93–99
  18. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA. 1994;272:1497–1505
  19. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The lung health study. Am J Respir Crit Care Med. 2000;161:381–390
  20. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789
  21. Tashkin DP, Celli B, Decramer M, et al. Regional patterns in the characteristics of patients recruited into a long-term global clinical trial in COPD (UPLIFT). Am J Respir Crit Care Med. 2005;2:A412;[Abstract]
  22. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26
  23. Pride NB. Smoking cessation: effects on symptoms, spirometry and future trends in COPD. Thorax. 2001;56(2):ii7–ii10
  24. Jiménez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001;119:1365–1370
  25. Willemse B, Lesman-Leegte I, Timens W, Postma D, ten Hacken N. High cessation rates of cigarette smoking in subjects with and without COPD. Chest. 2005;128:3685–3687
  26. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax. 2006;61:869–873
  27. Stratelis G, Mölstad S, Jakobsson P, Zetterström O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care. 2006;24:133–139
  28. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336:598–600
  29. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645–1648
  30. Murray RP, Johnston JJ, Dolce JJ, Lee WW, O'Hara P. Social support for smoking cessation and abstinence: the Lung Health Study. Lung health study research group. Addict Behav. 1995;20:159–170
  31. Murray RP, Gerald LB, Lindgren PG, Connett JE, Rand CS, Anthonisen NR. Characteristics of participants who stop smoking and sustain abstinence for 1 and 5 years in the lung health study. Prev Med. 2000;30:392–400
  32. Mannino DM, Doherty D, Buist AS, Holguin F. Global initiative on obstructive lung diseases (GOLD) classification of COPD and incident lung cancer: findings from a cohort study. Chest. 2004;126:853S;(Abstract)
  33. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128:2005–2011
  34. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med. 2003;114:10–14
  35. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005;60:570–575
  36. Wilson I. Depression in the patient with COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:61–64
  37. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675–679
  38. Simmons MS, Connett JE, Nides MA, et al. Smoking reduction and the rate of decline in FEV(1): results from the lung health study. Eur Respir J. 2005;25:1011–1017
  39. Hughes J, Lindgren P, Connett J, Nides M. Smoking reduction in the lung health study. Nicotine Tob Res. 2004;6:275–280
  40. Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res. 2006;8:739–749
  41. Murray RP, Anthonisen NR, Connett JE, et al. Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. J Clin Epidemiol. 1998;51:1317–1326
  42. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164:358–364
  43. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233–239
  44. Morgan MD, Britton JR. Chronic obstructive pulmonary disease 8: non-pharmacological management of COPD. Thorax. 2003;58:453–457
  45. Murray RP. The effect of the physician message on smoking cessation in the Lung Health Study. In: Annual Meeting of the American Thoracic Society; 20–24 May 1990; Boston, MA.
  46. Nelson M, Hamilton HE. Improving in-office discussion of chronic obstructive pulmonary disease: results and recommendations from an in-office linguistic study in chronic obstructive pulmonary disease. Am J Med. 2007;120:S28–S32
  47. Stead LF, Perera R, Lancaster T. A systematic review of interventions for smokers who contact quitlines. Tob Control. 2007;16:i3–i8
  48. Murray RP, Connett JE, Rand CS, Pan W, Anthonisen NR. Persistence of the effect of the lung health study (LHS) smoking intervention over eleven years. Prev Med. 2002;35:314–319
  49. Crowley TJ, Macdonald MJ, Walter MI. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology (Berl). 1995;119:193–204
  50. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001;357:1571–1575
  51. van der Meer RM, Wagena EJ, Ostelo RWJG, Jacobs JE, van Schayck CP. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003;2:CD002999
  52. Wagena EJ, van der Meer RM, Ostelo RJ, Jacobs JE, van Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med. 2004;98:805–815
  53. Christenhusz L, Pieterse M, Seydel E, van der Palen J. Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Educ Counsel. 2007;66:162–166
  54. Nides M, Rand C, Dolce J, et al. Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the lung health study. Health Psychol. 1994;13:354–361
  55. Wise RA, Enright PL, Connett JE, et al. Effect of weight gain on pulmonary function after smoking cessation in the lung health study. Am J Respir Crit Care Med. 1998;157:866–872
  56. O'Hara P, Connett JE, Lee WW, Nides M, Murray R, Wise R. Early and late weight gain following smoking cessation in the lung health study. Am J Epidemiol. 1998;148:821–830
  57. Luker KA, Chalmers KI, Caress AL, Salmon MP. Smoking cessation interventions in chronic obstructive pulmonary disease and the role of the family: a systematic literature review. J Adv Nurs. 2007;59:559–568
  58. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;CD000146
  59. Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest. 2006;130:334–342
  60. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the lung health study. Lung health study research group. Chest. 1996;109:438–445
  61. Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study, submitted for publication.
  62. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691
  63. Schapira RM, Reinke LF. The outpatient diagnosis and management of chronic obstructive pulmonary disease: pharmacotherapy, administration of supplemental oxygen, and smoking cessation techniques. J Gen Intern Med. 1995;10:40–55
  64. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med. 2005;165:2286–2292
  65. Lerman C, Shields PG, Wileyto EP, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 2003;22:541–548
  66. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl). 2003;168:347–358
  67. Maskos U, Molles BE, Pons S, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005;436:103–107
  68. Coe JW, Brooks PR, Wirtz MC, et al. 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005;15:4889–4897
  69. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55
  70. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63
  71. Shah SD, Wilken LA, Winkler SR, Lin S-J. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc. 2008;48:659–695
  72. Kuehn BM. Updated US smoking cessation guideline advises counseling, combining therapies. JAMA. 2008;299:2736

PII: S0954-6111(09)00065-1

doi: 10.1016/j.rmed.2009.02.013

Respiratory Medicine
Volume 103, Issue 7 , Pages 963-974 , July 2009

Article Tools

* Image Usage & Resolution